InvestorsHub Logo

H2R

Followers 42
Posts 2160
Boards Moderated 0
Alias Born 07/17/2014

H2R

Re: H2R post# 1432

Wednesday, 08/02/2017 9:17:07 PM

Wednesday, August 02, 2017 9:17:07 PM

Post# of 1569
Expected VITALITY-ALS Phase 3: Q4 2017 tracking!
Second Quarter 2017 Financial Results


Results Expected from VITALITY-ALS, Our Phase 3 Clinical Trial of Tirasemtiv, in Q4 2017

CK-2127107 Advancing in Four Clinical Trials Under Our Collaboration with Astellas

Omecamtiv Mecarbil Phase 3 Clinical Trial Proceeding on Plan in GALACTIC-HF Under Our Collaboration with Amgen

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYTK News